ArticleScientific reports2026
Plasma p-tau217, quantified by the fully automated LUMIPULSE G platform, outperforms p-tau181 in predicting amyloid pathology in cognitive complaints patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Plasma phosphorylated tau (p-tau) biomarkers offer a minimally invasive alternative for detecting Alzheimer’s disease (AD) pathology. We evaluated the diagnostic performance of plasma p-tau217 relative to p-tau181 using the fully automated LUMIPULSE platform. A total of 494 consecutively recruited patients with cognitive complaints from the Coimbra cohort were divided into exploratory and internal validation sets, and an external set of 100 well-characterized patients with mild cognitive impairment was obtained from Lisbon. Plasma biomarkers were assessed in relation to cerebrospinal fluid (CSF) AD biomarkers and evaluated their ability to detect amyloid pathology, defined by the CSF Aβ42/40 ratio. In the exploratory dataset, plasma p-tau217 showed stronger correlations with CSF biomarkers and higher accuracy in identifying amyloid positivity than p-tau181 (AUC = 0.90 vs. 0.81, p < 0.001). Age and blood urea nitrogen had minimal influence on p-tau217’s performance. Applying the Youden-derived single p-tau217 cutoff achieved an overall agreement of 88% with CSF-defined amyloid status across both validation sets. In addition, we evaluated a two-cutoff framework (95% sensitivity/specificity), which reduced misclassification and confined fewer than 30% of individuals to an intermediate, confirmatory-testing zone. These findings support the potential of plasma p-tau217 as a scalable blood-based biomarker that can aid triage and diagnostic decision-making in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.